EP2557923A4 - Treatment of cancers having k-ras mutations - Google Patents
Treatment of cancers having k-ras mutationsInfo
- Publication number
- EP2557923A4 EP2557923A4 EP11769663.3A EP11769663A EP2557923A4 EP 2557923 A4 EP2557923 A4 EP 2557923A4 EP 11769663 A EP11769663 A EP 11769663A EP 2557923 A4 EP2557923 A4 EP 2557923A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancers
- treatment
- ras mutations
- ras
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32491210P | 2010-04-16 | 2010-04-16 | |
PCT/US2011/032683 WO2011130628A1 (en) | 2010-04-16 | 2011-04-15 | Treatment of cancers having k-ras mutations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2557923A1 EP2557923A1 (en) | 2013-02-20 |
EP2557923A4 true EP2557923A4 (en) | 2013-10-23 |
Family
ID=44799046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11769663.3A Withdrawn EP2557923A4 (en) | 2010-04-16 | 2011-04-15 | Treatment of cancers having k-ras mutations |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2557923A4 (en) |
JP (1) | JP2013525308A (en) |
CN (1) | CN102970868A (en) |
AU (1) | AU2011239537A1 (en) |
CA (1) | CA2795952A1 (en) |
WO (1) | WO2011130628A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA016388B1 (en) * | 2006-09-15 | 2012-04-30 | Пфайзер Продактс Инк. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
MX2011007326A (en) | 2009-01-08 | 2011-10-19 | Curis Inc | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety. |
PT2694075T (en) | 2011-04-01 | 2016-07-11 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
ES2575143T3 (en) * | 2011-11-23 | 2016-06-24 | Cancer Research Technology Limited | Atypical protein kinase C thienopyridine inhibitors |
US8940742B2 (en) * | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3053926B1 (en) * | 2013-09-30 | 2018-08-08 | Shanghai Yingli Pharmaceutical Co. Ltd. | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
EP3054952B1 (en) * | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
KR20220140042A (en) * | 2013-11-15 | 2022-10-17 | 온코슈틱스 인코포레이티드 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use |
CN103601745B (en) * | 2013-11-26 | 2017-01-18 | 大连联化化学有限公司 | Preparation method of commonly used acetamidopyridine boronic acid pinacol ester |
PT3125898T (en) * | 2014-03-31 | 2020-04-01 | Scripps Research Inst | Pharmacophore for trail induction |
CN104131034B (en) * | 2014-06-19 | 2017-04-05 | 中山大学 | A kind of chimeric vector and its preparation method and application |
CN107205392B (en) | 2015-01-30 | 2020-06-09 | 巴斯夫欧洲公司 | Herbicidal phenylpyrimidines |
WO2016169417A1 (en) * | 2015-04-21 | 2016-10-27 | 成都金瑞长青生物科技有限公司 | Purinyl-n-hydroxyl pyrimidine formamide derivatives, preparation method therefor and use thereof |
CN105037345B (en) * | 2015-06-09 | 2019-01-25 | 天津渤海职业技术学院 | Antitumoral compounds, preparation method and use |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
CA3034010A1 (en) | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
EP3521290A4 (en) * | 2016-09-29 | 2020-04-22 | Daiichi Sankyo Company, Limited | Crystals of [2-(1-methyl-1h-pyrazol-4-yl)-6-(morpholin-4-yl)-9h-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof |
CN118206529A (en) | 2017-09-04 | 2024-06-18 | C4医药公司 | Dihydrobenzimidazolone |
US11351156B2 (en) | 2017-10-13 | 2022-06-07 | Inserm | Combination treatment of pancreatic cancer |
MX2020011991A (en) * | 2018-05-10 | 2021-04-12 | Univ Louisville Res Found Inc | Inhibitors of the ras oncoprotein, methods of making and methods of use thereof. |
EP3849554A4 (en) | 2018-09-11 | 2022-06-01 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
JP7407461B2 (en) * | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | Compounds that interact with the RAS superfamily for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
AU2021280893A1 (en) | 2020-05-08 | 2023-01-05 | Halia Therapeutics, Inc. | Inhibitors of NEK7 kinase |
EP4161511A4 (en) * | 2020-06-04 | 2024-07-17 | Pillai Universal Llc | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
CN113735830B (en) * | 2021-10-11 | 2024-08-20 | 成都自豪药业有限公司 | Hydroxamic acid derivative and application thereof |
WO2024041519A1 (en) * | 2022-08-24 | 2024-02-29 | 上海璎黎药业有限公司 | Morpholinyl quinazoline compound, and pharmaceutical composition and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097449A1 (en) * | 2005-03-15 | 2006-09-21 | Menarini International Operations Luxembourg S.A. | N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations |
WO2008076447A2 (en) * | 2006-12-15 | 2008-06-26 | Ordway Research Institute | Treatments of therapy-resistant diseases comprising drug combinations |
WO2009129335A2 (en) * | 2008-04-15 | 2009-10-22 | Pharmacyclics, Inc. | Selective inhibitors of histone deacetylase |
WO2009155659A1 (en) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101507182B1 (en) * | 2006-12-07 | 2015-03-30 | 제넨테크, 인크. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
WO2008100985A2 (en) * | 2007-02-15 | 2008-08-21 | Novartis Ag | Combination of lbh589 with other therapeutic agents for treating cancer |
MX2011007326A (en) * | 2009-01-08 | 2011-10-19 | Curis Inc | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety. |
-
2011
- 2011-04-15 WO PCT/US2011/032683 patent/WO2011130628A1/en active Application Filing
- 2011-04-15 JP JP2013505177A patent/JP2013525308A/en active Pending
- 2011-04-15 AU AU2011239537A patent/AU2011239537A1/en not_active Abandoned
- 2011-04-15 CA CA2795952A patent/CA2795952A1/en not_active Abandoned
- 2011-04-15 CN CN2011800290564A patent/CN102970868A/en active Pending
- 2011-04-15 EP EP11769663.3A patent/EP2557923A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006097449A1 (en) * | 2005-03-15 | 2006-09-21 | Menarini International Operations Luxembourg S.A. | N-hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations |
WO2008076447A2 (en) * | 2006-12-15 | 2008-06-26 | Ordway Research Institute | Treatments of therapy-resistant diseases comprising drug combinations |
WO2009129335A2 (en) * | 2008-04-15 | 2009-10-22 | Pharmacyclics, Inc. | Selective inhibitors of histone deacetylase |
WO2009155659A1 (en) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
Non-Patent Citations (14)
Title |
---|
CHIA-WEI CHOU ET AL: "HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells", PLOS ONE, vol. 6, no. 3, 25 March 2011 (2011-03-25), pages e18087, XP055078579, DOI: 10.1371/journal.pone.0018087 * |
DENLINGER ET AL: "Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 130, no. 5, 1 November 2005 (2005-11-01), pages 1422 - 1429, XP005127283, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2005.06.051 * |
E LOPEZ-CRAPEZ ET AL: "Rapid and large-scale method to detect K-ras gene mutations in tumor samples", CLINICAL CHEMISTRY, 1 January 1997 (1997-01-01), pages 936 - 942, XP055078570, Retrieved from the Internet <URL:http://www.clinchem.org/content/43/6/936.full.pdf+html> [retrieved on 20130910] * |
FRANKLIN WILBUR A ET AL: "KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cance", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 12, no. 1, 1 January 2010 (2010-01-01), pages 43 - 50, XP009168344, ISSN: 1525-1578 * |
G. J. RIELY ET AL: "KRAS Mutations in Non-Small Cell Lung Cancer", PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY, vol. 6, no. 2, 15 April 2009 (2009-04-15), pages 201 - 205, XP055024772, ISSN: 1546-3222, DOI: 10.1513/pats.200809-107LC * |
JEET GANDHI ET AL: "Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 2, 24 February 2009 (2009-02-24), pages E4576 - 1, XP002677508, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0004576 * |
KRYPUY MICHAEL ET AL: "High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 21 December 2006 (2006-12-21), pages 295, XP021023081, ISSN: 1471-2407, DOI: 10.1186/1471-2407-6-295 * |
M A LEA ET AL: "Induction of Differentiation of Colon Cancer Cells by Combined Inhibition of Kinases and Histone Deacetylase", ANTICANCER RESEARCH, vol. 27, 1 January 2007 (2007-01-01), pages 741 - 748, XP055079030 * |
N SUNAGA ET AL: "Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy", MOLECULAR CANCER THERAPEUTICS, vol. 10, 1 January 2011 (2011-01-01), pages 336 - 346, XP055079048 * |
PERGOLIZZI ROBERT G ET AL: "Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas", CANCER INVESTIGATION, vol. 11, no. 1, 1993, pages 25 - 32, XP008164834, ISSN: 0735-7907 * |
REDDY G K: "EARLY CLINICAL DATA AND POTENTIAL CLINICAL UTILITY OF NOVEL HISTONE DEACETYLASE INHIBITORS IN PROSTATE CANCER", CLINICAL PROSTATE CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 4, no. 2, 1 January 2005 (2005-01-01), pages 83 - 85, XP009079218, ISSN: 1540-0352 * |
See also references of WO2011130628A1 * |
WANG QINGDING ET AL: "Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2002, vol. 8, no. 6, June 2002 (2002-06-01), pages 1940 - 1947, XP055079069, ISSN: 1078-0432 * |
YU X-D ET AL: "Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 13, no. 2, 1 March 2007 (2007-03-01), pages 105 - 113, XP008111377, ISSN: 1528-9117 * |
Also Published As
Publication number | Publication date |
---|---|
CN102970868A (en) | 2013-03-13 |
CA2795952A1 (en) | 2011-10-20 |
EP2557923A1 (en) | 2013-02-20 |
AU2011239537A1 (en) | 2012-11-15 |
WO2011130628A1 (en) | 2011-10-20 |
JP2013525308A (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2557923A4 (en) | Treatment of cancers having k-ras mutations | |
IL276362A (en) | Methods of treating cancer | |
SG10201508495VA (en) | Combination treatment of cancer | |
HK1202253A1 (en) | Combination treatment of cancer | |
IL218575A0 (en) | Treatment of cancer | |
HRP20170225T1 (en) | Phosphaplatins and their use for treatment of cancers | |
HK1189272A1 (en) | Methods of treating cancer | |
EP2506875A4 (en) | Methods for treating cancers comprising k-ras mutations | |
EP2640390A4 (en) | Methods of treating cancer | |
PL388252A1 (en) | Combination therapy of colorectal cancer | |
GB0916686D0 (en) | Treatment of cancer | |
GB201017356D0 (en) | Combination treatment of cancer | |
GB201017354D0 (en) | Treatment of cancer | |
GB201002499D0 (en) | Treatment of tumours | |
GB201121791D0 (en) | Combination treatment of cancer | |
GB0921757D0 (en) | Treatment of cancer | |
GB201301168D0 (en) | Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1179472 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130924 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/19 20060101ALI20130918BHEP Ipc: A61K 45/06 20060101ALI20130918BHEP Ipc: A61K 31/167 20060101AFI20130918BHEP Ipc: A61K 31/496 20060101ALI20130918BHEP Ipc: A61K 31/4985 20060101ALI20130918BHEP Ipc: A61K 31/16 20060101ALI20130918BHEP Ipc: A61P 35/00 20060101ALI20130918BHEP Ipc: A61K 31/38 20060101ALI20130918BHEP Ipc: A61K 31/5355 20060101ALI20130918BHEP Ipc: A61K 31/343 20060101ALI20130918BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140423 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1179472 Country of ref document: HK |